Lytham Partners Summer 2021 Investor Conference

[wyattdog]

WESTLAKE VILLAGE, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the Lytham Partners Summer 2021 Investor Conference on Monday, June 14, 2021 at 11:45 AM (ET).



Interested parties can access a link to the webcast from the Events & Presentations section of the Company's website at www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.



About MannKind Corporation



MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, California, with a manufacturing and R&D facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. Please visit www.mannkindcorp.com to learn more.



Contact:

818-661-5000

[e-mail]

[ryster505]

Interesting no talk yet of how fabulous MC was today at Lytham?? Well, it was great..Have a listen

[mango]

✅ Confirmed

Receptor Life Sciences Phase 1 this year

———————————

Side note: Was there any mention of the NCE we just acquired? I have yet to listen to the entire conference, only just a few minutes of it.

[Clement]

I heard nothing about Thirona Bio.

[Clement]

At bottom of slide 6 it says
"* 4 assets to be out-licensed".
What assets? When? Including those already out-licensed?

[peppy]

Jun 14, 2021 12:58:37 GMT -5 Clement said:

At bottom of slide 6 it says
"* 4 assets to be out-licensed".
What assets? When? Including those already out-licensed?

epinephrine, for 1.

[peppy]

Jun 14, 2021 13:05:46 GMT -5 peppy said:

Jun 14, 2021 12:58:37 GMT -5 Clement said:

At bottom of slide 6 it says
"* 4 assets to be out-licensed".
What assets? When? Including those already out-licensed?

epinephrine, for 1.


The next team member has to guess next.

[cjm18]

Sharing Afrezza growth plan with shareholders soon.

480m in tyvaso sales last year. Analyst sales projection slide was interesting.

[mango]

Looks like the IPF molecule is still up for guesses since Thirona was not mentioned for it.

My guess remains with Samumed molecule licensed out to UT, specifically designed for inhalation and for IPF. 😎

[mango]

Jun 14, 2021 13:05:46 GMT -5 peppy said:

Jun 14, 2021 12:58:37 GMT -5 Clement said:

At bottom of slide 6 it says
"* 4 assets to be out-licensed".
What assets? When? Including those already out-licensed?

epinephrine, for 1.

Yes, possibly, but it’s not on the pipeline.

I could be wrong, but I believe MC is alluding to:

MNKD 101 — NTM/Clofazimine
MNKD 201 — IPF (Molecule remains undisclosed/My guess remains Samumed molecule out licensed to UT)
MNKD 301 — Dnase (confirmed today) for Cystic Fibrosis
MNKD 701 — Undisclosed target indication/Undisclosed molecule

[brentie]

Here's the slides...


seekingalpha.com/article/4434750-lytham-partners-summer-2021-investor-conference?mail_subject=mnkd-lytham-partners-summer-2021-investor-conference&utm_campaign=rta-stock-article&utm_content=link-2&utm_medium=email&utm_source=seeking_alpha

[peppy]

Jun 14, 2021 13:22:23 GMT -5 mango said:

Jun 14, 2021 13:05:46 GMT -5 peppy said:

epinephrine, for 1.

Yes, possibly, but it’s not on the pipeline.

I could be wrong, but I believe MC is alluding to:

MNKD 101 — NTM/Clofazimine
MNKD 201 — IPF (Molecule remains undisclosed/My guess remains Samumed molecule out licensed to UT)
MNKD 301 — Dnase (confirmed today) for Cystic Fibrosis
MNKD 701 — Undisclosed target indication/Undisclosed molecule

I tell the board, I can be wrong. 



2018. I am stuck in a time capsule. It used to be For license. 

[neil36]

He included (again) slide 12 which displays the Oppenheimer projections for UTHR product lines.

For Tyvaso Oppenheimer projects:

2021: $594.3 million
2022: $840.2 million
2023: $1.2049 billion
2024: $1.5692 billion

If UTHR were to only hit 85% of those numbers and only 85% of patients converted to DPI, that would mean sales of $1.133 billion in 2024, with 10% of that going to Mannkind, PLUS cost-plus manufacturing revenues.  Quite the positive cash-flow once DPI gets approved.

My guess is the nebulizer gets retired before 2024 and all patients will be converted to DPI.

[sla55]

Transcript:

seekingalpha.com/article/4434782-mannkind-corporation-mnkd-ceo-michael-castagna-presents-lytham-partners-summer-2021-investor?mail_subject=mnkd-mannkind-corporation-mnkd-management-presents-at-lytham-partners-summer-2021-investor-conference-transcript&utm_campaign=rta-stock-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha

[Deleted]

Jun 14, 2021 13:05:46 GMT -5 peppy said:

Jun 14, 2021 12:58:37 GMT -5 Clement said:

At bottom of slide 6 it says
"* 4 assets to be out-licensed".
What assets? When? Including those already out-licensed?

epinephrine, for 1.

Maybe Sumatriptan (Migrane - GSK)